bioRxivCancer Biology
New GFAP splice isoform (GFAPμ) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein
E. van Bodegraven, J. A. Sluijs, K. A. Tan, P. A. J. T. Robe, E. M. Hol
Abstract
The glial fibrillary acidic protein (GFAP) is a type III intermediate filament (IF) protein that is highly expressed in astrocytes, neural stem cells, and in gliomas. Gliomas are a heterogeneous group of primary brain tumors that arise from glia cells or neural stem cells and rely on accurate diagnosis for prognosis and treatment strategies. GFAP is differentially expressed between glioma subtypes and therefore often used as a diagnostic marker. However, GFAP is highly regulated by the process of alternative splicing; many different isoforms have been identified. Differential expression of GFAP isoforms between glioma subtypes suggests that GFAP isoform-specific analyses could benefit diagnostics. In this study we report on the differential expression of a new GFAP isoform between glioma subtypes, GFAPμ. A short GFAP transcript resulting from GFAP exon 2 skipping was detected by RNA sequencing of human glioma. We show that GFAPμ mRNA is expressed in healthy brain tissue, glioma cell lines, and primary glioma cells and that it translates into a ~21 kDa GFAP protein. 21 kDa GFAP protein was detected in the IF protein fraction isolated from human spinal cord as well. We further show that induced GFAPμ expression disrupts the GFAP IF network. The characterization of this new GFAP isoform adds on to the numerous previously identified GFAP splice isoforms. It emphasizes the importance of studying the contribution of IF splice variants to specialized functions of the IF network and to glioma diagnostics.Summary statement RNA sequencing data of glioma patient material reveals the differential expression of a short GFAP splice isoform, GFAPμ, between glioma subtypes. GFAPμ translates into a 21 kDa N-terminal GFAP protein which can disrupt the GFAP intermediate filament network.View Full Text
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence
J. V. van Asperen, R. Uceda-Castro, … E. M. Hol·bioRxiv·Aug 19, 2021
- Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform.
Guy Helman, Asako Takanohashi, … Cas Simons·Human MutationPeer-reviewed·Mar 3, 2020
- Validated method for automated glioma diagnosis from GFAP immunohistological images: a complete pipeline
Aurora Campo, F. Fernández-Flores, Martí Batlle Pumarola·bioRxiv·Jan 9, 2022
- Glioma-BioDP: Database for Visualization of Molecular Profiles to Improve Prognosis of Brain Cancer
U. Shankavaram, S. Das, … K. Camphausen·bioRxiv·Jun 9, 2022
- Deregulating m6A regulators leads to altered RNA biology in glioma cell lines
Syeda Maheen Batool, Hanna Lee, … Leonora Balaj·bioRxiv·Oct 28, 2024
- MUC1 and MUC4 expression are inversely correlated and trigger immunological response and transport pathways in gliomas
Gabriel Cardoso Machado, Valéria Pereira Ferrer·Computers in Biology and MedicinePeer-reviewed·Jan 30, 2025